Abstract:Inflammatory bowel disease (IBD) is chronic relapsing condition that affects 6.8 million people worldwide and unfortunately there is no cure (1) . Treatment, typically via anti-inflammatory medications, aims to induce remission and for many they are effective but for some they can lead to unpleasant side effects (2,3) . Anti-inflammatory nutraceuticals such as curcumin have, in recent years, shown potential for the treatment of IBD, however, there are limitations for its use including poor solubility and inadequate concentrations at target tissues (4–6) .Targeted delivery systems have the potential to reduce drug side effects and overcome some of the challenges for nutraceuticals. Hydrogels are a type of delivery system that can be easily tuned to target specific tissues, but there are challenges incorporating active ingredients such as curcumin. Therefore, microspheres can help overcome some challenges including solubility issues and act as a carrier for drugs and nutraceuticals within the hydrogel. Hence, the aim of the current study was to incorporate curcumin and dexamethasone loaded microspheres into a hydrogel that can target the specific features of IBD. An emulsion solvent evaporation technique was utilised to entrap dexamethasone (0.4wt%) and curcumin (0.4wt%) in polylactic acid-polyethylene glycol microspheres. Subsequently, 100 mg (0.5wt%) of each (dexamethasone and curcumin microspheres) were incorporated into hydrogels which were synthesised using polyethylene glycol dimethacrylate (PEGDMA), acrylic acid, water and a photoinitiator, via UV photopolymerisation. Encapsulation of dexamethasone and curcumin and their release from microspheres were determined via UV spectroscopy. Characterisation tests including swelling studies in pH buffers 2.2 and 6.8 and ionic charge studies in positively methylene blue in both pH 2.2 and 6,8, were carried out to determine the hydrogels-co-microspheres ability to target specific features of IBD. Statistical analysis (paired T-Test) was carried out using OriginLab. Encapsulation studies showed that on average 29% of the dexamethasone and 92% of the curcumin were successfully encapsulated into the microspheres, however the subsequent release measured over 4 weeks was low with higher release of dexamethasone (17.45% ± 0.09%) compared to curcumin (0.02% ± 0.0007%). Swelling studies demonstrated the equilibrium water content (EWC), the ability of the hydrogel-co-microsphere to uptake its surrounding solution, with differences observed in response to changes in pH. In pH 6.8 they had a higher EWC compared to pH 2.2 (EWC = 53% ± 0.06% and 43% ± 0.01%, respectively). The ionic charge of the hydrogel-co-microspheres was negative as indicated by uptake of positively charged methylene blue solution, with uptake in pH 6.8 greater than in pH 2.2 (4.7μl ± 0.14 V 3.5μl ± 0.09, respectively p<0.05). Although further work is required, an advanced delivery system of microspheres encapsulating drugs and nutraceuticals embedded in a hydrogel that can target specific features of IBD has great potential for improving therapeutic efficacy.

One‐Pot Synthesis of pH‐Responsive Eudragit‐Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease

Budesonide loaded nanoparticles with pH-sensitive coating for improved mucosal targeting in mouse models of inflammatory bowel diseases

pH-responsive interface conversion efficient oral drug delivery platform for alleviating inflammatory bowel disease

Bifunctional Succinylated ε-Polylysine-Coated Mesoporous Silica Nanoparticles for pH-Responsive and Intracellular Drug Delivery Targeting the Colon

A Programmable Oral Nanomotor Microcapsule for the Treatment of Inflammatory Bowel Disease

Reactive oxygen species-scavenging hollow MnO2 nanozymes as carriers to deliver budesonide for synergistic inflammatory bowel disease therapy

Oral hydrogel nanoemulsion co-delivery system treats inflammatory bowel disease via anti-inflammatory and promoting intestinal mucosa repair

Orally administered mesoporous silica capped with the cucurbit[8]uril complex to combat colitis and improve intestinal homeostasis by targeting the gut microbiota

Dual-Sensitive Carbohydrate-Based Nanosystem for Targeted Drug Delivery to Potentiate the Therapeutic Efficacy of Ulcerative Colitis

Orally Administrated Nucleotide-Delivery Particles from Microfluidics for Inflammatory Bowel Disease Treatment

Oral delivery of porous starch-loaded bilayer microgels for controlled drug delivery and treatment of ulcerative colitis

pH-Sensitive Tacrolimus loaded nanostructured lipid carriers for the treatment of inflammatory bowel disease

Multi-effect formulation based on pH-Responsive psyllium Mucilage/Poly(vinyl alcohol) nanofibers for controlled delivery of mesalamine

Multifunctional hydrogels for the delivery of drugs and nutraceuticals for the treatment of inflammatory bowel disease

Eudragit S100 coated microsponges for Colon targeting of prednisolone

A Mesoporous Polydopamine-Derived Nanomedicine for Targeted and Synergistic Treatment of Inflammatory Bowel Disease by Ph-Responsive Drug Release and ROS Scavenging

pH and redox dual response nano-suppository for the treatment of ulcerative colitis

Targeted delivery of budesonide in acetic acid induced colitis: impact on miR-21 and E-cadherin expression

Colon-targeted Oral Nanoparticles Based on ROS-scavenging Hydroxyethyl Starch-Curcumin Conjugates for Efficient Inflammatory Bowel Disease Therapy.

Alginate/methacrylic Acid/calcium Ion-Based Ph-Sensitive Drug Delivery Hydrogel for the Treatment of Ulcerative Colitis

Budesonide-Loaded Eudragit S 100 Nanocapsules for the Treatment of Acetic Acid-Induced Colitis in Animal Model